Search results
Showing 61 to 75 of 1376 results for 0
Evidence-based recommendations on capivasertib (Truqap) with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment in adults.
In development Reference number: GID-IPG10392 Expected publication date: TBC
Biomarker tests to help diagnose preterm labour in women with intact membranes (HTG476)
Evidence-based recommendations on biomarker tests to help diagnose preterm labour in women with intact membranes. The tests are Actim Partus, PartoSure and the Rapid fetal fibronectin (fFN) 10Q Cassette Kit (at thresholds other than 50 nanograms/millilitre).
Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for plaque psoriasis in children and young people.
Evidence-based recommendations on PneuX to prevent ventilator-associated pneumonia.
View recommendations for MTG48Show all sections
Transcatheter tricuspid valve implantation for symptomatic severe tricuspid regurgitation
In development Reference number: GID-IPG10416 Expected publication date: 04 March 2026
Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]
In development Reference number: GID-TA10250 Expected publication date: TBC
Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making
HumiGard for preventing inadvertent perioperative hypothermia (MTG31)
Evidence-based recommendations on HumiGard for preventing inadvertent perioperative hypothermia.
In development Reference number: GID-IPG10413 Expected publication date: 29 January 2026
Leadless cardiac pacemaker implantation for bradyarrhythmias
In development Reference number: GID-IPG10340 Expected publication date: 25 February 2026
Chronic anal fissure: 2% topical diltiazem hydrochloride (ESUOM3)
Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)
Evidence-based recommendations on carmustine implants (Gliadel) and temozolomide for treating newly diagnosed high-grade glioma in adults.
View recommendations for TA121Show all sections